Multiple Sclerosis

Illinois

56 Multiple Sclerosis Trials near Illinois

Power is an online platform that helps thousands of Multiple Sclerosis patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication
Active on Power

Frexalimab for Multiple Sclerosis

Northbrook, Illinois
The study is evaluating the efficacy and safety of Frexalimab in patients with non-relapsing, secondary progressive MS. The primary objective is to determine whether Frexalimab can delay disability progression compared to placebo.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 60

858 Participants Needed

Active on Power

Frexalimab for Multiple Sclerosis

Northbrook, Illinois
The study is evaluating whether Frexalimab performs better than the existing MS medication, Teriflunomide, at reducing the number of relapses in patients with relapsing forms of multiple sclerosis.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 55

1400 Participants Needed

Ofatumumab for Multiple Sclerosis

Saint Louis, Missouri
This study will evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of a new dosage of ofatumumab compared to the approved dosage of ofatumumab followed by extended treatment in participants with relapsing multiple sclerosis.
No Placebo Group
Prior Safety Data
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

180 Participants Needed

Remibrutinib vs Teriflunomide for Multiple Sclerosis

Merrillville, Indiana
This trial compares two medications, remibrutinib and teriflunomide, for treating patients with relapsing multiple sclerosis. These patients have repeated episodes of symptoms and need effective treatments. The medications work by controlling the immune system to prevent it from causing damage to the nervous system. Teriflunomide is an approved medication for adults with relapsing multiple sclerosis.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 55

800 Participants Needed

Remibrutinib vs Teriflunomide for Multiple Sclerosis

Springfield, Illinois
This trial compares remibrutinib and teriflunomide in patients with relapsing multiple sclerosis. It aims to find out which medication is more effective and safer. Both drugs work by controlling the immune system to reduce relapses. Teriflunomide is an approved treatment for adults with this condition.
No Placebo Group
Prior Safety Data
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 55

800 Participants Needed

Ofatumumab + Siponimod vs Fingolimod for Pediatric Multiple Sclerosis

Saint Louis, Missouri
This trial tests three medications in children and teens with multiple sclerosis to find effective treatments. The drugs work by reducing harmful immune cells or preventing them from attacking the nervous system.
Prior Safety Data
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:10 - 17

129 Participants Needed

High-Dose Ocrelizumab for Multiple Sclerosis

Saint Louis, Missouri
This trial is testing if a higher dose of ocrelizumab given through an IV drip is more effective and safe for patients with Primary Progressive Multiple Sclerosis (PPMS). The drug works by reducing harmful immune cells to potentially slow down the disease. Ocrelizumab is the first drug approved for treating both relapsing and primary progressive forms of multiple sclerosis.
No Placebo Group
Prior Safety Data
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18 - 55

769 Participants Needed

Stem Cell Transplant vs Best Available Therapy for Multiple Sclerosis

Evanston, Illinois
This is a multi-center prospective rater-masked (blinded) randomized controlled trial of 156 participants, comparing the treatment strategy of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) to the treatment strategy of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized at a 1 to 1 (1:1) ratio. All participants will be followed for 72 months after randomization (Day 0, Visit 0).
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 55

156 Participants Needed

Tolebrutinib for Multiple Sclerosis

Saint Louis, Missouri
This is a Phase 3 extension, global, multicenter study to assess the long-term safety and tolerability of tolebrutinib in adult participants (aged ≥18 years) with RMS, PPMS, or NRSPMS who were previously enrolled in the Phase 2b LTS (LTS16004) or 1 of the 4 Phase 3 tolebrutinib pivotal trials (GEMINI 1 \[EFC16033\], GEMINI 2 \[EFC16034\], HERCULES \[EFC16645\], or PERSEUS \[EFC16035\]). SUBSTUDY: ToleDYNAMIC substudy
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

2500 Participants Needed

Ublituximab for Multiple Sclerosis

Chicago, Illinois
The primary purpose of this phase 3b study is to assess the efficacy of a modified regimen of ublituximab as measured by T1 Gadolinium (Gd)-enhancing lesions and pharmacokinetics in participants with Relapsing Multiple Sclerosis (RMS). The study consists of 2 parts: Part A is single-armed and open-label and Part B is randomized, double-blind, placebo-controlled.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 65

600 Participants Needed

Ocrelizumab vs Fingolimod for Pediatric Multiple Sclerosis

Saint Louis, Missouri
This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with RRMS aged between 10 and \< 18 years over a flexible duration. The double-blind period will last until after the last participant randomized has completed 24 weeks.
Prior Safety Data
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:10 - 17

171 Participants Needed

Fenebrutinib for Relapsing Multiple Sclerosis

Saint Louis, Missouri
A study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS. Eligible participants will be randomized 1:1 to either fenebrutinib or teriflunomide. At the end of the DBT phase (after disclosure of the DBT results), the Sponsor will determine whether or not to initiate the open-label extension phase of the study.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18 - 55

746 Participants Needed

Tolebrutinib for Primary Progressive Multiple Sclerosis

Northbrook, Illinois
Primary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple sclerosis (PPMS) Secondary Objectives: To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic resonance imaging (MRI) lesions, cognitive performance, physical function, and quality of life To evaluate safety and tolerability of SAR442168 To evaluate population pharmacokinetics (PK) of SAR442168 in PPMS and its relationship to efficacy and safety To evaluate pharmacodynamics of SAR442168
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18 - 55

767 Participants Needed

Ozanimod for Multiple Sclerosis

Saint Louis, Missouri
This is a multicenter, longitudinal, single-arm, open-label study to describe the change from baseline in cognitive processing speed, measured by the SDMT, in subjects with RMS treated with ozanimod HCl 1 mg at 3 years. All subjects will receive orally administered ozanimod HCl 1 mg. The primary efficacy endpoint is the proportion of subjects with a clinically meaningful increase in raw score of ≥ 4 points or 10% from baseline (improved). The treatment period is 36 months. For all subjects who finish the subject and for those who discontinue, there will be a 30-day (± 15 days) and a 90-day (± 10 days) Safety Follow-up Visit. There is no planned protocol extension following the end of the study. Approximately 250 subjects with RMS will be recruited for this study. Subjects with RMS will be enrolled in this study if they have received ≤ 1 DMT, have an EDSS ≤ 3.5, and have been diagnosed with RMS within 5 years of study entry. The Investigator will be responsible for the overall conduct of the study at the site, confirmation of subject eligibility, routine study subject clinical management including for MS relapses, and management of AEs.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18 - 65

250 Participants Needed

Ublituximab for Multiple Sclerosis

Northbrook, Illinois
The purpose of this study is to evaluate long-term safety and efficacy of ublituximab therapy in participants with relapsing multiple sclerosis (RMS).
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

1100 Participants Needed

Ocrelizumab for Progressive Multiple Sclerosis

Chicago, Illinois
This study is a prospective, multicenter, open-label, single-arm effectiveness and safety study in participants with progressive multiple sclerosis (PMS).
No Placebo Group
Prior Safety Data
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18 - 65

927 Participants Needed

Ozanimod vs Fingolimod for Multiple Sclerosis

Chicago, Illinois
The purpose of this study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS).
Prior Safety Data
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:10 - 17

194 Participants Needed

Ofatumumab for Multiple Sclerosis

Winfield, Illinois
This study will evaluate whether ofatumumab is excreted at quantifiable levels and at which concentrations in breast milk of lactating women with RMS). The study will include lactating mothers who plan to breastfeed and initiate/re-initiate ofatumumab 2-24 weeks post-partum.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4
Sex:Female

20 Participants Needed

Cladribine for Multiple Sclerosis

Saint Louis, Missouri
The purpose of this study is to better understand the mechanism of action (MoA) of cladribine tablets by exploring the effect on central nervous system (CNS) and blood biomarkers relevant in the relapsing forms of multiple sclerosis (RMS; to include relapsing-remitting MS \[RRMS\] or active secondary progressive MS).
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 4
Age:18 - 65

47 Participants Needed

EMR-Based Treatment for Neurological Disorders

Evanston, Illinois
The investigators will conduct at NorthShore University HealthSystem pragmatic trials using the EMR for 10 common neurological disorders. They will demonstrate the feasibility of subgroup based adaptive assignment of treatments, electronic consenting, and outcomes data capture at the point of care using the EMR. They will identify the most effective treatments for common neurological disorders and seek replication by the NPBRN.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Phase 4

3300 Participants Needed

Why Other Patients Applied

"I've tried 2 MS drugs but I am getting worse. I am having trouble walking long distances or for more than 30 minutes. I need to find a new medication. My doctor and I discussed some of the options in trials and I'm ready to dive in to learn more."

OL
Multiple Sclerosis PatientAge: 57

"I am 42 yrs old with 2 little kids, work as a nurse, tried several drugs, most made me feel awful. I want my quality of life. I don’t want to have to take something daily/monthly. I don’t like the side effects of many drugs. I'm excited to be considered as a candidate for one of these trials."

KT
Multiple Sclerosis PatientAge: 44

"I have been losing mobility in the past 3 years very rapidly. I have tried physical therapy, but it didn't really show results. I'll admit that I am not very self-motivated, so I can use some structure. I use to be extremely active and now I am like a wet rag. So I am hoping that participating in a research trial will be of help to me."

AK
Multiple Sclerosis PatientAge: 75

"I've been taking Kesimpta for a couple years now and seem to be having more flare ups. I'm only 43. I have 5 kids and feel like I'm missing my life. Sleeping my life away. I'm ready to try ANYTHING for a chance at living life again."

XJ
Multiple Sclerosis PatientAge: 43

"I've been using natural supplements and would like to find something more effective. My former PCP was hesitant to prescribe modafanil. I'm interested in learning about all options available to me—including the drugs currently under research investigation."

GK
Multiple Sclerosis PatientAge: 50

Ocrelizumab for Multiple Sclerosis

Saint Louis, Missouri
This trial is testing if patients with early relapsing multiple sclerosis can stop taking Ocrelizumab after initial treatment without their disease getting worse. Ocrelizumab is a medication given through an IV that helps manage multiple sclerosis by reducing harmful immune cells. The study will monitor patients for new disease activity over several years.
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4
Age:18 - 55

123 Participants Needed

PIPE-307 for Multiple Sclerosis

Saint Louis, Missouri
This trial is testing a new drug called PIPE-307 to see if it can help people with relapsing-remitting multiple sclerosis. The drug likely works by calming the immune system to prevent nerve damage. The study will compare two different doses of PIPE-307 over several months.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 50

168 Participants Needed

Obexelimab for Multiple Sclerosis

Saint Louis, Missouri
This study aims to examine the efficacy and safety of obexelimab in participants with relapsing multiple sclerosis

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 60

93 Participants Needed

LY3541860 for Multiple Sclerosis

Northbrook, Illinois
The main purpose of this study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and gets better. The study will last about 9 months with additional 6 months follow-up.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 55

200 Participants Needed

BIIB091 for Relapsing Multiple Sclerosis

Saint Louis, Missouri
In this study, researchers will learn more about a study drug called BIIB091 in participants with MS who may be experiencing relapses. It is a 2-part study. In Part 1, one set of participants will take either BIIB091 or diroximel fumarate (DRF). In Part 2, a different set of participants will take either a combination of BIIB091 and DRF or DRF alone. The goal of the study is to learn more about the safety of BIIB091 and to compare the effects of the study drug when taken alone or together with DRF. The main question researchers are trying to answer are: * How many participants have new or worsening medical problems (adverse events) after taking BIIB091 or DRF? * How many new areas of inflammation occur in the brain after treatment with BIIB091 and DRF? Researchers will use magnetic resonance imaging (MRI) scans to compare images of the brain before and after treatment. They will also explore the effect of BIIB091 and DRF on the heart using electrocardiograms (ECGs). The study will be done as follows: * After screening, participants who joined Part 1 will be randomly assigned to receive either a high or low dose of BIIB091, or the standard dose of DRF. * The results of Part 1 will be used to choose the best dose of BIIB091 to use in Part 2. * Participants who join Part 2 will be randomly assigned to receive either a standard dose of DRF, a combo of BIIB091 and the standard dose of DRF, or a combo of BIIB91 with a low dose of DRF. * Neither the researchers nor the participants will know which drug or dose the participants will receive in either part of the study. * The treatment period will last 48 weeks in each part of the study. Participants will take the drugs by mouth 2 times a day. * Each part will also have a follow-up safety period that lasts up to 2 weeks. * In total, participants in each part will have 20 study visits, or more if they have a relapse. The total study duration for participants will be up to 54 weeks.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 55

275 Participants Needed

Orelabrutinib for Multiple Sclerosis

Northbrook, Illinois
This trial is testing Orelabrutinib, a medication for people with Relapsing-Remitting Multiple Sclerosis. It aims to reduce immune cell activity that causes attacks on the nervous system, potentially lowering the frequency and severity of relapses.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 55

160 Participants Needed

Ocrelizumab for Pediatric Multiple Sclerosis

Saint Louis, Missouri
This 2-year study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic (PD) effects of ocrelizumab in children and adolescents ages ≥ 10 to ≤ 18 years with relapsing-remitting multiple sclerosis (RRMS). The data from this study will serve to determine the dosing regimen of ocrelizumab to be further investigated in the subsequent Phase III study in children and adolescents.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:10 - 18

23 Participants Needed

MSCopilot App for Multiple Sclerosis

St Louis, Missouri
This US multicenter, prospective cohort study aims to evaluate how MSCopilot can be seamlessly integrated into the current care pathway and identify potential optimizations to enhance its impact on both MS patients and clinicians, facilitating broader implementation. Specifically, the study will assess: * The overall integration of MSCopilot into routine clinical practice, * Patients' ability to use MSCopilot at home without supervision, * The need for patient support when using MSCopilot at home, * User behavior based on usage analytics data from the MSCopilot mobile app and dashboard, * Patient adherence to MSCopilot use in routine clinical practice, * The adequacy of the onboarding/training process for HCPs, * The effectiveness of HCPs onboarding/training in ensuring successful patient onboarding, * The variances in user behavior and adherence to MSCopilot use according to socio-demographic factors and EDSS scores
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased

100 Participants Needed

Exercise Rehabilitation for Multiple Sclerosis

Chicago, Illinois
Approximately 50% of people with multiple sclerosis (MS) use a wheelchair within 30 years of the initial diagnosis. Wheelchair use in MS is often associated with fatigue as a consequence of muscle weakness. Indeed, fatigue, a prevalent consequence of MS, often becomes debilitating and exhausts energetic resources when carrying-out tasks of daily life and/or interacting with the community, as these require ambulatory mobility. This experience of excessive fatigue has its roots in muscle weakness and results in reliance on a wheelchair for mobility, and the dependency on a wheelchair may further reduce muscular strength, particularly of the lower extremities. We propose that wheelchair users with MS can increase muscular strength through a personalized exercise rehabilitation, and this in turn will improve ambulatory performance and possibly reduce fatigue. To date, no research has examined the effects of this specific exercise rehabilitation program (GH method) on physical function and other disease-related outcomes in persons with MS who use wheelchairs as a primary mobility device.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

24 Participants Needed

Acute Intermittent Hypoxia for Multiple Sclerosis

Chicago, Illinois
This study seeks to explore changes in the neural pathways and arm function following a breathing intervention in the multiple sclerosis (MS) population. The breathing intervention, known as Acute Intermittent Hypoxia (AIH), involves breathing brief bouts of low levels of oxygen. Research has found AIH to be a safe and effective intervention resulting in increased ankle strength in people with MS. Here, the study examines arm and hand function before and after AIH. In order to better understand the brain and spinal cord response to AIH, the investigators will measure muscle response, and signals sent from the brain to the arm muscles before and after AIH.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased

22 Participants Needed

12

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Multiple Sclerosis clinical trials in Illinois pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Multiple Sclerosis clinical trials in Illinois work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Multiple Sclerosis trials in Illinois 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Illinois for Multiple Sclerosis is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Illinois several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Multiple Sclerosis medical study in Illinois?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Multiple Sclerosis clinical trials in Illinois?

Most recently, we added BMS-986368 for Multiple Sclerosis, MSCopilot App for Multiple Sclerosis and Ozanimod vs Fingolimod for Multiple Sclerosis to the Power online platform.

Can MS go into remission?

Yes. In relapsing-remitting MS the immune attack can quiet down for weeks, months, or even years, letting symptoms ease or disappear; neurologists try to extend these quiet spells—called remission or “no evidence of disease activity” (NEDA)—with early use of disease-modifying drugs, healthy habits, and regular MRI checks. Remission isn’t a cure because slow nerve damage can still smolder, and it is uncommon in secondary- or primary-progressive MS, so sticking with treatment and follow-up appointments remains vital even when you feel well.

What is the most common cause of death in MS patients?

Death certificates show that the commonest “underlying” cause of death in people with MS is the disease itself (ICD-10 G35), accounting for roughly half of all deaths; this label usually stands for advanced disability complicated by infections and breathing problems. Cardiovascular disease and cancer trail well behind (each about one-tenth to one-fifth of deaths), so focusing on preventing aspiration, treating infections quickly, staying mobile, and managing heart-health risks offers the biggest leverage for living longer with MS.

What not to do if you have MS?

Think of “don’ts” in three buckets: 1) anything that drives inflammation (smoking, heavy drinking, high-salt or highly processed, high-saturated-fat foods); 2) anything that lets the body decondition or overheat (long periods of inactivity, extreme heat without cooling strategies); and 3) anything that interferes with treatment safety (skipping or delaying prescribed medicines, starting high-dose supplements or live vaccines, or stopping disease-modifying therapy without your neurologist’s okay). Steering clear of these pitfalls, while staying active, eating mostly whole foods, and working closely with your MS team, gives the best chance of slowing attacks and disability.

What is the new test for MS?

Doctors now have a spinal-fluid test called the “kappa free light-chain (KFLC) index,” which measures tiny antibody pieces instead of looking for oligoclonal bands. In several large studies it identified multiple sclerosis with about 90–95 % sensitivity and 85–90 % specificity, is run on an automated machine (so it’s faster, cheaper, and less subjective), and many centers are beginning to add it to the standard work-up, although it still requires a lumbar puncture and currently complements rather than fully replaces oligoclonal-band testing.

Is MS a disability?

Multiple sclerosis is recognized by disability laws in the U.S., U.K., Canada and many other countries, but you are considered “disabled” only if your specific symptoms—such as fatigue, vision loss, or mobility problems—limit everyday tasks or steady work despite treatment. Because MS progression varies widely (some stay mild for decades while roughly one-third need a cane within 15 years), keep detailed medical records and talk with your neurologist, employer, or a benefits adviser early to document limitations, request job accommodations, or file for disability support if needed.

How many brain lesions are normal with MS?

There isn’t a “normal” or required lesion count for multiple sclerosis: some people have none on the first MRI, others show a handful, and studies put the typical range at roughly 5–15 lesions. What matters more to doctors is where the spots are and whether new ones appear over time—four or more lesions, especially in key areas like around the ventricles, can raise concern for future disability, but prognosis depends on the pattern and evolution rather than any single number.

Has anyone reversed MS?

So far no treatment has reliably “turned MS off” for everyone, but limited reversal of disability can occur. Many patients regain some or all lost function after a relapse, and small clinical trials of autologous stem-cell transplantation show that about 50-70 % of carefully selected, highly active cases improve their disability scores for several years, though the procedure carries notable risks and is not yet routine care. Current disease-modifying drugs aim to prevent new damage, and research into remyelination medicines is underway, but a guaranteed, widely available way to reverse MS does not yet exist.

Are MS cases on the rise?

Yes, the head-count of people living with multiple sclerosis is climbing worldwide—up roughly one-third since 1990—largely because people are being diagnosed earlier and living longer with the disease. New cases per year (incidence) have risen only modestly and unevenly, suggesting that improved detection and better treatments, rather than an explosive growth in risk, account for most of the increase, though lifestyle factors such as low vitamin D, obesity, smoking and EBV infection may also play a smaller role.

Does MS run in families?

MS can cluster in families, but it is not passed down in a simple all-or-nothing way: the lifetime chance is about 1 in 300 for anyone, rises to roughly 1 in 30 (≈2–3 %) if you have a parent, child, or sibling with MS, and even identical twins match only about 1 in 4 times—proof that genes are only part of the story. Because most relatives never develop the disease, routine genetic testing isn’t recommended; instead, general health steps that may lower risk (adequate vitamin D, avoiding smoking, healthy weight) are sensible for everyone.

What is the progressive treatment for MS?

Treatment for progressive MS has two parts. First, disease-modifying drugs such as ocrelizumab (for primary-progressive) and siponimod or, in some cases, cladribine/rituximab (for active secondary-progressive) can slow further disability when started early under an MS specialist’s care. Second, an ongoing personalised plan—physiotherapy and exercise, medicines for spasticity, pain, bladder or fatigue, plus good sleep, diet, vaccination and prompt treatment of infections—helps control day-to-day symptoms and prevents complications, with regular reviews to adjust both pieces as the condition evolves.

Popular Searches

By Condition

Depression Clinical Trials

Anxiety Clinical Trials

Schizophrenia Clinical Trials

ADHD Clinical Trials

Bipolar Disorder Clinical Trials

Multiple Sclerosis Clinical Trials

Autism Clinical Trials

Treatment Resistant Depression Clinical Trials

Borderline Personality Disorder Clinical Trials

Social Anxiety Disorder Clinical Trials

Parkinson's Disease Clinical Trials

Alzheimer's Disease Clinical Trials

By Location

Clinical Trials in California

Clinical Trials in Florida

Clinical Trials in Texas

Clinical Trials in New York

Clinical Trials in Ohio

Clinical Trials in Illinois

Clinical Trials in Pennsylvania

Clinical Trials in Michigan

Clinical Trials in North Carolina

Clinical Trials in Massachusetts

Clinical Trials in Missouri

Clinical Trials in Minnesota

Other People Viewed

By Subject

Top Depression Clinical Trials near Newark, NJ

107 Clinical Trials near Keene, NH

Top Lung Cancer Clinical Trials near Miami, FL

31 Parkinson's Disease Trials near Denver, CO

Top Thymoma Clinical Trials

Top Temporomandibular Joint Clinical Trials

Top Clinical Trials near Cocoa, FL

36 Schizophrenia Trials near Irvine, CA

19 Bipolar Disorder Trials near Washington, DC

Top Clinical Trials near Corvallis, OR

169 Clinical Trials near Clayton, NC

Top Clinical Trials near Arcadia, CA

By Trial

Tucatinib + Radiation for Breast Cancer

Renal Denervation for High Blood Pressure

L606 Inhalation Suspension for Pulmonary Arterial Hypertension

Xaluritamig for Prostate Cancer

DRP-104 + Durvalumab for Cancer

Voice Analysis Technology for Heart Attack Recovery

Cannabidiol for Chronic Pain

STX-241 for Lung Cancer

Embedded Multidisciplinary Diabetes Clinic for Diabetes

In-Person vs Telehealth Cardiac Rehab for Heart Disease

Transdermal Metronidazole Absorption in Healthy Volunteers

Methadone for Pain Management in Cardiac Surgery

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial